

Led by a visionary executive team, the Ceribell Rapid Response EEG system is the first critical care EEG and quickly becoming an important vital sign for the brain.

Executive Team




Jane Chao, PhD

CEO and Co-founder

Jane Chao, the co-founder and CEO of Ceribell, holds a Ph.D. in biophysics from Cornell University. Before she joined Ceribell, Jane had a solid history of leadership and success in business. She launched her career as a management consultant with McKinsey & Company, and later made her move into the medical space joining Novartis as their Senior Strategy Manager. She then enjoyed a successful career at Genentech as their Principal Manager of Portfolio Management Strategy.


In 2015, Jane started Ceribell full-time as the CEO, the position she currently holds. She has built and led the Ceribell team from early concept stages to a fully commercial, FDA-cleared, clinically proven and highly successful commercial product that is changing the standard of care for critically ill patients.



Raymond Woo, PhD

CTO

Raymond Woo joined Ceribell in 2016 to lead its product research and development efforts. Throughout his career, Ray has worked to successfully bring innovative and disruptive medical device technologies to market. Prior to Ceribell, he was Global Head of Femtosecond Laser R&D at Abbott Medical Optics (now a part of J&J Vision), where he was responsible for R&D efforts across multiple product lines in both the laser cataract surgery and the laser vision correction markets. He helped to develop the Catalys laser cataract surgery system at Optimedica, which was acquired by Abbott Medical Optics. Ray received a Ph.D. and Master's degree in Electrical Engineering from Stanford University, where his research focused on novel semiconductor devices. He has a Bachelor's degree in Electrical Engineering and Computer Science from Duke University.



Scott Blumberg

CFO

Scott Blumberg, Ceribell's CFO, has over 15 years of healthcare finance experience, largely focused on the medical device space. Prior to joining Ceribell, Scott served as Managing Advisor of Venture Forward Advisory Services, a financial and strategic consulting agency that he founded. At Venture Forward, served as a trusted advisor and outsourced CFO to 20+ venture-backed startups and emerging growth companies, completing over 100 engagements. Previously, Scott served as Director of Business Development for IDEV Technologies, a Houston based venture-backed medical device company, where he led strategic initiatives including implementing an advanced sales analytics program, sourcing and negotiating multiple partnerships, developing marketing strategies, and leading the M&A process that resulted in a \$310 million sale to Abbott. Scott previously served as investment professional at Bay City Capital, a San Francisco based life sciences venture capital firm, and an investment banking analyst at Bank of America. Scott holds a BA in economics with a minor in psychology from Dartmouth College.



David Stoffel, MD

CBO

David Stoffel, M.D., Ceribell's Chief Business Officer, has over 20 years of experience in the medical device industry and has an extensive track record of developing and commercializing innovative technologies. Before joining Ceribell, David was responsible for leading the Mobile Cardiac Telemetry (MCT) business at iRhythm Technologies, one of the fastest-growing digital health companies. Prior to iRhythm, he led the Marketing and Business Development functions at Intuitive Surgical where he helped build the revolutionary Da Vinci robotic system into a new surgical standard of care. An experienced investor, David has also been a partner at Radius Ventures, a healthcare venture capital firm and he started his career in investment banking at Credit Suisse. David has a Bachelor's degree in Economics from Stanford University and a combined MD/MBA from the University of Chicago.



Sandy Thompson

Senior VP of Sales

Sandy Thompson, Ceribell's Senior VP of Sales, has over 20 years of commercial medical device leadership experience in Fortune 500 and start-up organizations. He has held multiple national commercial leadership roles running divisions with both disruptive technologies and diverse portfolios. Sandy has consistently delivered exceptional business results in highly competitive existing and emerging markets and built outstanding teams and organizations with the highest employee motivation and satisfaction levels. He has a tremendous ability to establish mutually beneficial and lasting cross-functional customer partnerships at all levels. Sandy has an excellent track record of attracting, retaining, and developing talents that become future leaders within the organization. He is very adept at building commercial organizations from the ground up. Sandy joined Ceribell in 2019 and built the commercial team from the ground up and grew YOY business by 400%, followed by 2020 by 300% YOY growth.



Rafael Donnay

VP of Product & Growth

Rafael Donnay, Ceribell's VP of Strategy, joined Ceribell in 2018 with over 15 years of US and international experience in the medtech industry. He started his career in engineering and product development at St. Jude Medical. He then joined Ardian (acquired by Medtronic) and helped commercialize the novel device-based treatment for hypertension in over 80 countries. Rafael then held marketing leadership roles at Stryker Neurovascular and Philips Image Guided Therapies. Rafael holds a B.S. from Columbia University, M.S. from Stanford University, and an MBA from the Wharton School of the University of Pennsylvania.



Dan Rogy

VP of Operations

Dan Rogy, Ceribell's VP of Operation, has over 25 years of medical equipment and disposable device Operations and R&D management experience. He led the R&D and Operation Teams at Outset Medical to commercialize a novel Hemodialysis system. Dan was General Manager at Abbott Laboratories, after the acquisition of OptiMedica, where he was responsible for all medical capital equipment and disposable device operations.

Previously he was Director of R&D at Adiana, acquired by Cytoc Corporation, leading the development and manufacturing of a complex disposable with implant and RF Generator. He also held operational management roles at Eli Lilly/Guidant Corporation supplying equipment to manufacturing sites in England, Ireland and the US. Dan has multiple patents for disposable and implant devices and completed his business degree at Illinois Central College.